HGT-1110

Biologic

Takeda

HGT-1110 is one of 7 biologic programs targeting Metachromatic Leukodystrophy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metachromatic LeukodystrophyActive, not recruiting

Metachromatic LeukodystrophyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Metachromatic Leukodystrophy

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Approved

—2

Cytoxan

BBaxter Healthcare Corporation

RG6026

SHP611

Recombinant Human Arylsulfatase a

Takeda

Phase 2

2 6

Coumadin

AAbbott

Preclinical

1 7

HGT-1110

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metachromatic Leukodystrophy1 trial

An Efficacy and Safety Study of HGT-1110 in Participants With Metachromatic Leukodystrophy

Active, not recruiting· Takeda logo

Takeda·Phase 1/2·NCT01887938·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HGT-1110. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HGT-1110 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HGT-1110. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Takeda

HGT-1110

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metachromatic Leukodystrophy1 trial

References

Drug Info

Quick Facts

Related News